The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety
as preventive therapy of the immunomodulatory substance named copaxone which had been proven
as safe and effective agent for a neurodegenerative disease, in arresting the progression as
well as the conversion of dry AMD to wet AMD. The hypothesis that the immunomodulatory agent
copaxone proven for a neurodegenerative disease may work in the eye is revolutionary and may
open a new avenue of preventive treatment for the disease which is the major cause of legal
blindness in the industrial world
1. Dry AMD in one or both eyes
2. Age 50 or above of either gender
3. Signed informed consent.
1. Known sensitivity to Mannitol or Copaxone.
2. Skin disease or active infection of skin.
3. Active fever or active treatment for infection.
4. History of other uncontrolled systemic active disease.
5. Premenopausal females not using reliable birth control.
6. Sensitivity to fluorescein or iodine.
7. Inability to comply with study procedures.